Prostate Cancer Ontology
Center for Systems Biology, Sichuan University West China Hospital, Sichuan China
跳过导航链接。
折叠 Prostate cancerProstate cancer
展开 Epidemiological aspects of prostate cancerEpidemiological aspects of prostate cancer
展开 Diagnostic aspects of prostate cancerDiagnostic aspects of prostate cancer
折叠 Therapeutic aspects of prostate cancerTherapeutic aspects of prostate cancer
展开 Deferred treatmentDeferred treatment
展开 SurgerySurgery
折叠 RadiotherapyRadiotherapy
展开 CryotherapyCryotherapy
展开 Hormonal therapyHormonal therapy
展开 ChemotherapyChemotherapy
展开 Castration-resistant prostate cancer (CRPC)Castration-resistant prostate cancer (CRPC)
展开 Metastatic prostate cancerMetastatic prostate cancer
展开 Other treatmentOther treatment
Ra-233
Preferred Name Mopidamol
Definition A derivative of dipyridamole that is a phosphodiesterase inhibitor, with potential antiplatelet activity. Mopidamol inhibits the hydrolysis of cyclic nucleotides, such as cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), by cyclic nucleotide phosphodiesterases; thus, cAMP- and cGMP-dependent processes are potentiated. This leads to the induction of prostacyclin synthesis, the inhibition of thromboxane B2 synthesis and prevention of platelet activation and aggregation.
Synonyms & Abbreviations 2,2',2",2"'-[(4-Piperidinopyrimido[5,4-d-]pyrimidine-2,6-diyl)dinitrilo]tetraethanol
2,2',2",2"'-[[4-(1-Piperidinyl)pyrimido[5,4-d]pyrimidine-2,6-diyl]dinitrilo]tetrakisethanol
2,6-Bis(diethanolamino)-4-piperidino-pyrimido[5,4-d]pyrimidine
MOPIDAMOL
Mopidamol
RA-233
Rapenton
ReferenceCode NCI Thesaurus Code:C668
ReferenceURL https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C668
PMID NA
Copyright (C) 2022 Institutes for Systems Genetics, Sichuan University West China Hospital. All Rights Reserved.